| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 49 |
| 1 | CISPLATIN | 38 |
| 2 | NIVOLUMAB | 37 |
| 3 | PACLITAXEL | 35 |
| 4 | BEVACIZUMAB | 34 |
| 5 | GEMCITABINE HYDROCHLORIDE | 33 |
| 6 | DURVALUMAB | 23 |
| 7 | PEMETREXED DISODIUM | 22 |
| 8 | RIVAROXABAN | 18 |
| 9 | IPILIMUMAB | 17 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZOLBETUXIMAB | 8 | 0.0052 |
| 1 | CAFFEINE, MAGNESIUM SALICYLATE | 1 | 0.0039 |
| 2 | PAMABROM | 1 | 0.0027 |
| 3 | LEVOLEUCOVORIN INJECTION | 7 | 0.0023 |
| 4 | EDOXABAN TOSYLATE | 15 | 0.0022 |
| 5 | LEVOLEUCOVORIN | 7 | 0.0018 |
| 6 | NALDEMEDINE | 3 | 0.0018 |
| 7 | RAMUCIRUMAB | 8 | 0.0013 |
| 8 | ENFORTUMAB VEDOTIN | 9 | 0.0011 |
| 9 | LORLATINIB | 8 | 0.0011 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 8 | 0.0052 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 129 | 0.0013 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 8 | 0.0013 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 23 | 0.0011 |
| 4 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 5 | 0.0006 |
| 5 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 6 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 19 | 0.0004 |
| 8 | Platinum-based Drug [EPC] | 101 | 0.0004 |
| 9 | Amyloid Beta-directed Antibody [EPC] | 1 | 0.0003 |